| Selective Retina Therapy in Patients with Central Serous Chorioretinopathy. |
|
Jae Min Kim, Joo Yeon Kim |
|
Myung-Gok Eye Resarch Institute, Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea. redmanson@kimeye.com |
| 중심장액맥락망막병증 환자에서 선택적 망막치료술의 효과와 안전성 |
|
김재민⋅김주연 |
|
건양대학교 의과대학 김안과병원 안과학교실 명곡안연구소 |
Correspondence:
Joo Yeon Kim,
Email: redmanson@kimeye.com
|
|
Received: 14 December 2017 • Revised: 21 May 2018 • Accepted: 27 September 2018 |
| Abstract |
PURPOSE
We evaluated the visual outcomes and changes in central macular thickness in patients with central serous chorioretinopathy who underwent selective retina therapy. METHODS: Patients diagnosed with central serous chorioretinopathy were included in the study. Fundus fluorescein angiography was performed before laser treatment. We reviewed the charts of 16 patients (17 eyes) in terms of age, sex, best-corrected visual acuity, intraocular pressure, slit lamp examination, the time from diagnosis to laser treatment, the site of laser treatment and side-effects. Optical coherence tomography was performed before laser treatment and 1 month later; the central macular thicknesses were compared. RESULTS: The average best-corrected visual acuity at diagnosis and 1 month after laser treatment were 0.20 and 0.12 (logMAR) respectively. The improvement was thus 0.08 (logMAR). The average central macular thickness decreased by 174.78 µm from 326.53 ± 59 µm at baseline to 151.75 ± 15 μm 1 month after selective retina therapy. CONCLUSIONS: Selective laser therapy afforded favorable visual and structural outcomes and was not associated with a risk of scotoma or other untreatable side-effects. |
| Key Words:
Best correct visual acuity;Central macular thickness;Central serous chorioretinopathy;Selective retina therapy |
PDF Links
Full text via DOI
Download Citation
